<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749904</url>
  </required_header>
  <id_info>
    <org_study_id>769</org_study_id>
    <nct_id>NCT01749904</nct_id>
  </id_info>
  <brief_title>Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <acronym>APOLLO</acronym>
  <official_title>A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In participants with a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT),
      the primary objective is to demonstrate that the mean IOP reduction after 3 months of
      treatment with BOL-303259-X once daily (QD) is non-inferior to timolol maleate 0.5% twice
      daily (BID). The secondary objective is to demonstrate the superiority of BOL-303259-X QD to
      timolol maleate 0.5% BID. This assessment will be performed if the non-inferiority of
      BOL-303259-X QD to timolol maleate 0.5% BID is determined. An open label safety phase will be
      conducted at the end of Visit 6 (3 months) where all participants will receive BOL-303259-X
      QD for an additional 9 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2013</start_date>
  <completion_date type="Actual">September 30, 2015</completion_date>
  <primary_completion_date type="Actual">June 2, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean IOP</measure>
    <time_frame>8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3)</time_frame>
    <description>Mean intraocular pressure (IOP) in study eye measured at the specified time points: 8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate - IOP ≤ 18 mm Hg</measure>
    <time_frame>8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3).</time_frame>
    <description>Percentage of participants with IOP ≤ 18 mm Hg consistently at all 9 time points in the first 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate - IOP Reduction ≥ 25%</measure>
    <time_frame>8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3).</time_frame>
    <description>Percentage of participants with IOP reduction ≥ 25% consistently at all 9 time points in the first 3 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Ocular and Systemic Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Following assessments through Visit 6 (Month 3), all participants, irrespective of previous randomization, converted to a single open label safety arm receiving BOL-303259-X QD in the evening. Adverse events were recorded throughout the comparative efficacy phase and open label extension phase.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Open-Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>BOL-303259-X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-303259-X</intervention_name>
    <description>Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).</description>
    <arm_group_label>BOL-303259-X</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol</intervention_name>
    <description>Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)</description>
    <arm_group_label>Timolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-303259-X</intervention_name>
    <description>All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)</description>
    <arm_group_label>BOL-303259-X</arm_group_label>
    <arm_group_label>Timolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have a diagnosis of OAG (including pigmentary or pseudoexfoliative)
             or OHT in 1 or both eyes.

          -  Participants must meet the following IOP requirements at Visit 3

          -  mean/median IOP ≥ 24 mmHg at a minimum of 2 time points in the same eye

          -  IOP ≤ 36 mmHg at all 3 measurement time points in both eyes.

          -  Participants with a best-corrected visual acuity (BCVA), using the Early Treatment of
             Diabetic Retinopathy Study (ETDRS) protocol, of +0.7 logMAR units (Snellen equivalent
             of approximately 20/100) or better in either eye.

        Exclusion Criteria:

          -  Participants with known hypersensitivity or contraindications to latanoprost, NO
             treatment, timolol maleate, other beta-adrenergic receptor antagonists or any of the
             ingredients in the study drugs.

          -  Participants with a central corneal thickness greater than 600 μm in either eye.

          -  Participants with advanced glaucoma and participants with a cup/disc ratio greater
             than 0.8 or a history of split fixation, or a field loss threatening fixation in
             either eye.

          -  Participants who do not have an intact posterior capsule in either eye .

          -  Participants with aphakia in either eye.

          -  Participants with previous or active corneal disease in either eye.

          -  Participants with current or a history of severe dry eye in either eye.

          -  Participants with current or a history of optic disc hemorrhage in either eye.

          -  Participants with current or a history of central/branch retinal vein or artery
             occlusion in either eye.

          -  Participants with current or a history of macular edema in either eye.

          -  Participants with very narrow angles (3 quadrants with less than Grade 2 according to
             Shaffer's anterior chamber angle grading system) and Participants with angle
             closure,congenital, and secondary glaucoma, and participants with history of angle
             closure in either eye.

          -  Participants with a diagnosis of a clinically significant or progressive retinal
             disease in either eye.

          -  Participants with any intraocular infection or inflammation in either eye within 3
             months(90 days) prior to Visit 1 (Screening).

          -  Participants with a history of ocular laser surgery in either eye within the 3
             months(90 days) prior to Visit 1 (Screening).

          -  Participants with a history of incisional ocular surgery or severe trauma in either
             eye within 3 months (90 days) prior to Visit 1 (Screening).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Vittitow</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. Ophthalmology. 2016 May;123(5):965-73. doi: 10.1016/j.ophtha.2016.01.019. Epub 2016 Feb 11.</citation>
    <PMID>26875002</PMID>
  </results_reference>
  <results_reference>
    <citation>Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. J Glaucoma. 2018 Jan;27(1):7-15. doi: 10.1097/IJG.0000000000000831.</citation>
    <PMID>29194198</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 11, 2012</study_first_submitted>
  <study_first_submitted_qc>December 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <results_first_submitted>May 1, 2018</results_first_submitted>
  <results_first_submitted_qc>October 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 7, 2018</results_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intraocular pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BOL-303259-X</title>
          <description>BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
BOL-303259-X: Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
BOL-303259-X: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)</description>
        </group>
        <group group_id="P2">
          <title>Timolol</title>
          <description>Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
Timolol: Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
BOL-303259-X: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="286">randomized population</participants>
                <participants group_id="P2" count="134">randomized population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="264">randomized population</participants>
                <participants group_id="P2" count="123">randomized population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat population. Of the 420 subjects randomized, 418 instilled at least one dose of study medication and were included in the safety population, whereas one subject did not have any post-baseline efficacy reading, hence 417 subjects were included in the Intent-to-treat population</population>
      <group_list>
        <group group_id="B1">
          <title>BOL-303259-X</title>
          <description>BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye during the efficacy phase, and for an additional 9 months from Visit 6 through Visit 9 (1 year) during the open label safety extension phase</description>
        </group>
        <group group_id="B2">
          <title>Timolol</title>
          <description>Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye. thereafter these subjects were switched to receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="284"/>
            <count group_id="B2" value="133"/>
            <count group_id="B3" value="417"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="10.32"/>
                    <measurement group_id="B2" value="63.1" spread="11.23"/>
                    <measurement group_id="B3" value="64.2" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="374"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="325"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean IOP</title>
        <description>Mean intraocular pressure (IOP) in study eye measured at the specified time points: 8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3).</description>
        <time_frame>8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3)</time_frame>
        <population>Intent-to-treat population with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>BOL-303259-X</title>
            <description>BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
BOL-303259-X: Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
BOL-303259-X: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)</description>
          </group>
          <group group_id="O2">
            <title>Timolol</title>
            <description>Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
Timolol: Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
BOL-303259-X: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean IOP</title>
          <description>Mean intraocular pressure (IOP) in study eye measured at the specified time points: 8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3).</description>
          <population>Intent-to-treat population with LOCF</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 am week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.61" spread="3.544"/>
                    <measurement group_id="O2" value="19.84" spread="3.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 pm week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.00" spread="3.376"/>
                    <measurement group_id="O2" value="19.37" spread="3.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 pm week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.09" spread="3.293"/>
                    <measurement group_id="O2" value="19.20" spread="3.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 am week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="283"/>
                    <count group_id="O2" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.59" spread="3.525"/>
                    <measurement group_id="O2" value="19.63" spread="3.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 pm week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="283"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.84" spread="3.305"/>
                    <measurement group_id="O2" value="19.09" spread="3.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 pm week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="284"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.82" spread="3.513"/>
                    <measurement group_id="O2" value="19.09" spread="3.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 am Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="283"/>
                    <count group_id="O2" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.71" spread="3.382"/>
                    <measurement group_id="O2" value="19.73" spread="2.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 pm Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="283"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.88" spread="3.409"/>
                    <measurement group_id="O2" value="19.15" spread="3.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 pm Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="284"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.83" spread="3.521"/>
                    <measurement group_id="O2" value="19.15" spread="3.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The 2 treatments were compared for each time point by visit. LS mean of each treatment group, the difference in the LS mean, and the 2-sided 95% CI for the difference were obtained. Noninferiority could be claimed if the upper limit of the CIs &lt;1.5 mmHg at all time points of each visit and &lt;1.00 mmHg for at least 5 out of the 9 time points. If noninferiority was determined, superiority at each time point could be claimed if the upper limit of the 95% CI&lt;0 mmHg at all time points of each visit.</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>The ANCOVA results for the comparison of LS means of mean IOP between treatment groups demonstrated noninferiority of BOL-303259-X to timolol and also superiority of BOL-303259-X to timolol</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate - IOP ≤ 18 mm Hg</title>
        <description>Percentage of participants with IOP ≤ 18 mm Hg consistently at all 9 time points in the first 3 months</description>
        <time_frame>8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3).</time_frame>
        <population>Intent-to-treat population with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>BOL-303259-X</title>
            <description>BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
BOL-303259-X: Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
BOL-303259-X: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)</description>
          </group>
          <group group_id="O2">
            <title>Timolol</title>
            <description>Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
Timolol: Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
BOL-303259-X: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate - IOP ≤ 18 mm Hg</title>
          <description>Percentage of participants with IOP ≤ 18 mm Hg consistently at all 9 time points in the first 3 months</description>
          <population>Intent-to-treat population with LOCF</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate - IOP Reduction ≥ 25%</title>
        <description>Percentage of participants with IOP reduction ≥ 25% consistently at all 9 time points in the first 3 months</description>
        <time_frame>8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3).</time_frame>
        <population>Intent-to-treat with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>BOL-303259-X</title>
            <description>BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
BOL-303259-X: Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
BOL-303259-X: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)</description>
          </group>
          <group group_id="O2">
            <title>Timolol</title>
            <description>Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
Timolol: Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
BOL-303259-X: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate - IOP Reduction ≥ 25%</title>
          <description>Percentage of participants with IOP reduction ≥ 25% consistently at all 9 time points in the first 3 months</description>
          <population>Intent-to-treat with LOCF</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Ocular and Systemic Adverse Events</title>
        <description>Following assessments through Visit 6 (Month 3), all participants, irrespective of previous randomization, converted to a single open label safety arm receiving BOL-303259-X QD in the evening. Adverse events were recorded throughout the comparative efficacy phase and open label extension phase.</description>
        <time_frame>12 months</time_frame>
        <population>Safety population (analyzed as treated). Of the 420 subjects randomized, 418 instilled at least one dose of study medication and were included in the safety population; one subject randomized to BOL-303259-X received timolol in the efficacy phase and was therefore analyzed as part of the timolol treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>BOL-303259-X</title>
            <description>BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months into the study eye during the efficacy phase.</description>
          </group>
          <group group_id="O2">
            <title>Timolol</title>
            <description>Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months into study eye during the efficacy phase.</description>
          </group>
          <group group_id="O3">
            <title>BOL-303259-X Safety Extension Phase</title>
            <description>Following completion of the efficacy phase, all subjects were converted to BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) for an additional 9 months from Visit 6 through Visit 9 (1 year) during the open label safety extension phase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ocular and Systemic Adverse Events</title>
          <description>Following assessments through Visit 6 (Month 3), all participants, irrespective of previous randomization, converted to a single open label safety arm receiving BOL-303259-X QD in the evening. Adverse events were recorded throughout the comparative efficacy phase and open label extension phase.</description>
          <population>Safety population (analyzed as treated). Of the 420 subjects randomized, 418 instilled at least one dose of study medication and were included in the safety population; one subject randomized to BOL-303259-X received timolol in the efficacy phase and was therefore analyzed as part of the timolol treatment group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;/= 1 nonocular AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 1 ocular (Study eye) AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>No statistical analysis was performed on these proportions.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Safety Population (analyzed as treated). Of 420 subjects randomized, 418 instilled &gt;/=1 dose and were included in the Safety Population; 1 subject randomized to BOL-303259-X received timolol and was therefore analyzed as part of the timolol group in the efficacy phase of the study. All subjects were converted to BOL-303259-X during the safety extension phase and AEs reported during that phase are presented below as a third arm</desc>
      <group_list>
        <group group_id="E1">
          <title>BOL-303259-X</title>
          <description>BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months into the study eye during the efficacy phase.</description>
        </group>
        <group group_id="E2">
          <title>Timolol</title>
          <description>Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months into study eye during the efficacy phase.</description>
        </group>
        <group group_id="E3">
          <title>BOL-303259-X Safety Extension Phase</title>
          <description>Following completion of the efficacy phase, all subjects were converted to BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) for an additional 9 months from Visit 6 through Visit 9 (1 year) during the open label safety extension phase</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="283"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dislocation of intraocular lens</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic angioedema due to Motrin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="385"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spider bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="385"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="385"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="385"/>
              </event>
              <event>
                <sub_title>Fracture of right femoral neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>torn rotator cuff</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Recurrence of breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="385"/>
              </event>
              <event>
                <sub_title>Right upper lobe lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="385"/>
              </event>
              <event>
                <sub_title>Leg disco-ordination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="385"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="283"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="283"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="385"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>H. DeCory, Director Medical Affairs</name_or_title>
      <organization>Bausch + Lomb, a division of Valeant Pharmaceuticals</organization>
      <phone>585 732-3284</phone>
      <email>heleen_H_decory@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

